Reynders McVeigh Capital Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $932K | Hold |
1,658
| – | – | 0.05% | 100 |
|
|
2025
Q4 | $1.12M | Hold |
1,658
| – | – | 0.05% | 92 |
|
|
2025
Q3 | $1.06M | Buy |
1,658
+7
| +0.4% | +$4.25K | 0.05% | 99 |
|
|
2025
Q2 | $885K | Buy |
1,651
+1
| +0.1% | +$478 | 0.04% | 106 |
|
|
2025
Q1 | $693K | Hold |
1,650
| – | – | 0.04% | 117 |
|
|
2024
Q4 | $682K | Sell |
1,650
-10
| -0.6% | -$4.39K | 0.04% | 122 |
|
|
2024
Q3 | $839K | Buy |
1,660
+10
| +0.6% | +$4.86K | 0.04% | 111 |
|
|
2024
Q2 | $804K | Hold |
1,650
| – | – | 0.05% | 104 |
|
|
2024
Q1 | $891K | Sell |
1,650
-10
| -0.6% | -$5.46K | 0.05% | 100 |
|
|
2023
Q4 | $921K | Hold |
1,660
| – | – | 0.06% | 97 |
|
|
2023
Q3 | $726K | Hold |
1,660
| – | – | 0.05% | 107 |
|
|
2023
Q2 | $834K | Buy |
1,660
+10
| +0.6% | +$4.79K | 0.05% | 103 |
|
|
2023
Q1 | $825K | Sell |
1,650
-148
| -8% | -$70.8K | 0.06% | 100 |
|
|
2022
Q4 | $734K | Buy |
1,798
+143
| +9% | +$55.5K | 0.05% | 110 |
|
|
2022
Q3 | $539K | Hold |
1,655
| – | – | 0.04% | 128 |
|
|
2022
Q2 | $580K | Hold |
1,655
| – | – | 0.04% | 134 |
|
|
2022
Q1 | $905K | Sell |
1,655
-26
| -2% | -$13.7K | 0.06% | 112 |
|
|
2021
Q4 | $1.11M | Buy |
1,681
+2
| +0.1% | +$1.26K | 0.06% | 107 |
|
|
2021
Q3 | $1.04M | Buy |
1,679
+350
| +26% | +$235K | 0.06% | 104 |
|
|
2021
Q2 | $839K | Sell |
1,329
-391
| -23% | -$216K | 0.05% | 116 |
|
|
2021
Q1 | $842K | Buy |
1,720
+66
| +4% | +$33.1K | 0.06% | 113 |
|
|
2020
Q4 | $827K | Buy |
1,654
+124
| +8% | +$55.5K | 0.06% | 116 |
|
|
2020
Q3 | $601K | Hold |
1,530
| – | – | 0.05% | 136 |
|
|
2020
Q2 | $505K | Hold |
1,530
| – | – | 0.04% | 137 |
|
|
2020
Q1 | $371K | Hold |
1,530
| – | – | 0.04% | 140 |
|
|
2019
Q4 | $400K | Buy |
1,530
+300
| +24% | +$79.1K | 0.04% | 165 |
|
|
2019
Q3 | $334K | Hold |
1,230
| – | – | 0.04% | 176 |
|
|
2019
Q2 | $339K | Sell |
1,230
-141
| -10% | -$34.7K | 0.04% | 171 |
|
|
2019
Q1 | $307K | Hold |
1,371
| – | – | 0.03% | 181 |
|
|
2018
Q4 | $255K | Sell |
1,371
-34
| -2% | -$6.97K | 0.03% | 185 |
|
|
2018
Q3 | $351K | Sell |
1,405
-25
| -2% | -$6.07K | 0.04% | 162 |
|
|
2018
Q2 | $312K | Buy |
1,430
+55
| +4% | +$11.3K | 0.04% | 171 |
|
|
2018
Q1 | $263K | Sell |
1,375
-75
| -5% | -$13.8K | 0.03% | 176 |
|
|
2017
Q4 | $227K | Sell |
1,450
-60
| -4% | -$9.44K | 0.03% | 193 |
|
|
2017
Q3 | $235K | Buy |
1,510
+60
| +4% | +$9.49K | 0.03% | 191 |
|
|
2017
Q2 | $234K | Hold |
1,450
| – | – | 0.03% | 203 |
|
|
2017
Q1 | $224K | Buy |
+1,450
| New | +$200K | 0.03% | 208 |
|
Other funds holding IDXX
VCM
VPM
Reynders McVeigh Capital Management's IDXX Position: Q1 2026 in Review
Reynders McVeigh Capital Management held its Idexx Laboratories (IDXX) position steady in Q1 2026 at 1,658 shares worth $932K. The position accounts for 0.05% of the portfolio, ranked #100.
Reynders McVeigh Capital Management first reported a position in IDXX in Q1 2017 and has held it in 37 quarters since. The position peaked at $1.12M in Q4 2025. 1,314 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.
- Reynders McVeigh Capital Management held 1,658 shares of Idexx Laboratories worth $932K as of Q1 2026.
- Reynders McVeigh Capital Management left its Idexx Laboratories share count unchanged in Q1 2026.
- Idexx Laboratories made up 0.05% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #100 holding.
- Reynders McVeigh Capital Management first reported a position in Idexx Laboratories in Q1 2017 and has held it in 37 quarters since.
- Reynders McVeigh Capital Management's Idexx Laboratories position peaked at $1.12M in Q4 2025.
- 1,314 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.
Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.